Howman-Giles R, Uren R F, Shaw P J
Department of Nuclear Medicine, Royal Alexandra Hospital for Children, Camperdown, Sydney, Australia.
J Nucl Med. 1995 Aug;36(8):1372-6.
Thallium-201 has been used as a tumor imaging agent in adults with lymphoma, brain tumors, thyroid carcinoma and bone sarcomas. The application of 201Tl in pediatric oncology has been very limited.
Whole-body 201Tl studies were incorporated into the imaging protocols of 45 children with solid soft-tissue tumors. Bone and 67Ga scans as well as 131I-MIBG scans for patients with neuroblastoma were obtained.
Seventeen children with lymphoma, five with Hodgkin's disease and twelve with non-Hodgkin's lymphoma (NHL) were studied. All of the patients with Hodgkin's disease showed avid uptake of 201Tl and 67Ga. The six patients with B-cell NHL had positive 67Ga scans and four had positive 201Tl scans. There was variable uptake in T-cell and undifferentiated lymphoma with an overall sensitivity of 69% for 201Tl and 85% for 67Ga. In 14 patients with rhabdomyosarcoma, 10 (71%) had positive 201Tl scans and 11 (79%) had positive 67Ga images. Gallium and thallium scans detected lesions equally. There was poor uptake of 201Tl in the six children with neuroblastoma. Primary tumor and metastases were detected more readily with the bone and MIBG scans. Three children with Wilms' tumor had poor or no uptake on 201Tl images, two of three patients with histocytosis had no significant uptake and one patient had mild uptake of 201Tl. One patient with primitive neuroectodermal tumor had positive 201Tl and 67Ga images and one patient with a neurofibrosarcoma had negative 201Tl and 67Ga images. There was no correlation with histological types of tumor or disease staging.
This study shows significant uptake of 201Tl in many pediatric solid soft-tissue tumors. Additional study is needed to determine 201Tl effects on treatment response and tumor viability. Also, more studies are needed to assess 201Tl delayed images to determine if there is more tracer concentration in the tumors.
铊-201已被用作淋巴瘤、脑肿瘤、甲状腺癌和骨肉瘤成年患者的肿瘤显像剂。铊-201在儿科肿瘤学中的应用非常有限。
全身铊-201检查被纳入45例实体软组织肿瘤患儿的成像方案中。对神经母细胞瘤患者进行了骨扫描、镓-67扫描以及碘-131间碘苄胍(131I-MIBG)扫描。
研究了17例淋巴瘤患儿,其中5例为霍奇金病,12例为非霍奇金淋巴瘤(NHL)。所有霍奇金病患者的铊-201和镓-67摄取均增强。6例B细胞NHL患者的镓-67扫描呈阳性,4例的铊-201扫描呈阳性。T细胞淋巴瘤和未分化淋巴瘤的摄取情况各不相同,铊-201的总体敏感性为69%,镓-67为85%。在14例横纹肌肉瘤患者中,10例(71%)的铊-201扫描呈阳性,11例(79%)的镓-67显像呈阳性。镓扫描和铊扫描对病变的检测效果相当。6例神经母细胞瘤患儿的铊-201摄取较差。骨扫描和MIBG扫描更容易检测到原发肿瘤和转移灶。3例肾母细胞瘤患儿的铊-201图像摄取较差或无摄取,3例组织细胞增多症患者中有2例无明显摄取,1例患者铊-201摄取轻度增加。1例原始神经外胚层肿瘤患者的铊-201和镓-67图像呈阳性,1例神经纤维肉瘤患者的铊-201和镓-67图像呈阴性。与肿瘤的组织学类型或疾病分期无相关性。
本研究显示铊-201在许多儿科实体软组织肿瘤中有明显摄取。需要进一步研究以确定铊-201对治疗反应和肿瘤活性的影响。此外,还需要更多研究来评估铊-201延迟图像,以确定肿瘤中是否有更多的示踪剂聚集。